[go: up one dir, main page]

MA52948A - Composés - Google Patents

Composés

Info

Publication number
MA52948A
MA52948A MA052948A MA52948A MA52948A MA 52948 A MA52948 A MA 52948A MA 052948 A MA052948 A MA 052948A MA 52948 A MA52948 A MA 52948A MA 52948 A MA52948 A MA 52948A
Authority
MA
Morocco
Prior art keywords
compounds
Prior art date
Application number
MA052948A
Other languages
English (en)
Other versions
MA52948B1 (fr
Inventor
Ylva Elisabet Bergman Bozikis
Michelle Ang Camerino
Richard Charles Foitzik
Catherine Fae Hemley
Helen Rachel Lagiakos
Benjamin Joseph Morrow
Paul Anthony Stupple
Scott Raymond Walker
Original Assignee
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctxt Pty Ltd filed Critical Ctxt Pty Ltd
Publication of MA52948A publication Critical patent/MA52948A/fr
Publication of MA52948B1 publication Critical patent/MA52948B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA52948A 2018-06-20 2019-06-20 Composés MA52948B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810092.5A GB201810092D0 (en) 2018-06-20 2018-06-20 Compounds
PCT/EP2019/066337 WO2019243491A1 (fr) 2018-06-20 2019-06-20 Composés

Publications (2)

Publication Number Publication Date
MA52948A true MA52948A (fr) 2021-04-28
MA52948B1 MA52948B1 (fr) 2024-02-29

Family

ID=63042663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52948A MA52948B1 (fr) 2018-06-20 2019-06-20 Composés

Country Status (39)

Country Link
US (2) US20200039945A1 (fr)
EP (2) EP3810602B1 (fr)
JP (2) JP2021529738A (fr)
KR (1) KR20210022655A (fr)
CN (1) CN112334466A (fr)
AR (1) AR114972A1 (fr)
AU (2) AU2019289888A1 (fr)
BR (1) BR112020025869A2 (fr)
CA (1) CA3101238A1 (fr)
CL (1) CL2020003219A1 (fr)
CO (1) CO2020014586A2 (fr)
CR (1) CR20210032A (fr)
CU (1) CU20200096A7 (fr)
DK (1) DK3810602T3 (fr)
DO (1) DOP2020000249A (fr)
EA (1) EA202092451A1 (fr)
EC (1) ECSP20075270A (fr)
ES (1) ES2967983T3 (fr)
FI (1) FI3810602T3 (fr)
GB (1) GB201810092D0 (fr)
GE (1) GEP20227403B (fr)
HR (1) HRP20231467T1 (fr)
HU (1) HUE064744T2 (fr)
IL (1) IL279554B2 (fr)
LT (1) LT3810602T (fr)
MA (1) MA52948B1 (fr)
MD (1) MD3810602T2 (fr)
MX (1) MX2020012723A (fr)
NI (1) NI202000092A (fr)
PE (1) PE20210181A1 (fr)
PH (1) PH12020500673A1 (fr)
PL (1) PL3810602T3 (fr)
PT (1) PT3810602T (fr)
RS (1) RS64932B1 (fr)
SG (1) SG11202010450VA (fr)
SI (1) SI3810602T1 (fr)
TW (1) TWI826471B (fr)
UY (1) UY38270A (fr)
WO (1) WO2019243491A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471271A1 (fr) 2017-10-16 2019-04-17 Acoustical Beauty Convolutions améliorées de signaux numériques utilisant une optimisation des exigences de bits d'un signal numérique cible
PT3986890T (pt) * 2019-06-18 2024-01-17 Ctxt Pty Ltd Derivados de benzisoxazol sulfonamida
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
EP3999490A4 (fr) * 2019-07-12 2023-03-08 Canopy Growth Corporation Dérivés cannabinoïdes
AU2021308406A1 (en) 2020-07-15 2023-02-23 Ctxt Pty Ltd KAT6 inhibitor methods and combinations for cancer treatment
AU2022278733A1 (en) * 2021-05-21 2023-11-30 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
US20240400545A1 (en) * 2021-07-05 2024-12-05 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
TW202321263A (zh) 2021-08-10 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 磺醯胺衍生物、其製備方法及其在醫藥上的應用
IL312696A (en) * 2021-11-16 2024-07-01 Insilico Medicine Ip Ltd Lysine acetyltransferase 6A (KAT6A) inhibitors and their uses
CA3241874A1 (fr) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Composes benzoisoxazolyle fusionnes en tant qu'inhibiteurs de kat6a
WO2023192817A1 (fr) 2022-03-28 2023-10-05 Isosterix, Inc. Inhibiteurs de la famille myst des lysine acétyltransférases
AU2023295547A1 (en) * 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
WO2024023703A1 (fr) 2022-07-29 2024-02-01 Pfizer Inc. Schémas posologiques comprenant un inhibiteur de kat6 pour le traitement du cancer
WO2024201334A1 (fr) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a en tant que biomarqueur prédictif pour un traitement avec un inhibiteur de kat6a et méthodes de traitement associées
WO2024217563A1 (fr) * 2023-04-19 2024-10-24 Insilico Medicine Ip Limited Inhibiteur de lysine acétyltransférase 6a (kat6a), associations et utilisations associées
WO2024222725A1 (fr) * 2023-04-25 2024-10-31 Insilico Medicine Ip Limited Inhibiteur de lysine acétyltransférase 6a (kat6a) cristallin et ses utilisations
WO2025007873A1 (fr) * 2023-07-04 2025-01-09 上海齐鲁制药研究中心有限公司 Inhibiteur de kat6

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ES2284200T3 (es) 1997-02-12 2007-11-01 Electrophoretics Limited Marcadores proteicos para cancer de pulmon y uso de los mismos.
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
DK1676845T3 (da) 1999-11-05 2008-09-15 Astrazeneca Ab Nye quinazolinderivater
PL211834B1 (pl) 2000-02-15 2012-06-29 Sugen Związki 2-indolinonowe, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
EP1289952A1 (fr) 2000-05-31 2003-03-12 AstraZeneca AB Derives d'indole possedant une activite endommageant les vaisseaux sanguins
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1301498A1 (fr) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Derives de colchinol utiles comme inhibiteurs de l'angiogenese
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
CA2747419C (fr) * 2009-01-12 2014-07-08 Icagen, Inc. Derives sulfonamides
MX2015010775A (es) * 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
AU2015251207B2 (en) * 2014-04-23 2019-08-22 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
PT3986890T (pt) * 2019-06-18 2024-01-17 Ctxt Pty Ltd Derivados de benzisoxazol sulfonamida

Also Published As

Publication number Publication date
JP2021529738A (ja) 2021-11-04
HRP20231467T1 (hr) 2024-03-01
NI202000092A (es) 2021-03-23
DOP2020000249A (es) 2021-02-28
LT3810602T (lt) 2024-01-25
SI3810602T1 (sl) 2024-02-29
JP2024133637A (ja) 2024-10-02
UY38270A (es) 2020-01-31
US20220153710A1 (en) 2022-05-19
MA52948B1 (fr) 2024-02-29
ES2967983T3 (es) 2024-05-06
AU2024278273A1 (en) 2025-01-02
MX2020012723A (es) 2021-05-14
CO2020014586A2 (es) 2021-03-08
CN112334466A (zh) 2021-02-05
EP3810602A1 (fr) 2021-04-28
AU2019289888A1 (en) 2020-11-12
CR20210032A (es) 2021-02-11
AR114972A1 (es) 2020-11-11
HUE064744T2 (hu) 2024-04-28
FI3810602T3 (fi) 2023-12-21
WO2019243491A1 (fr) 2019-12-26
CA3101238A1 (fr) 2019-12-26
TW202016103A (zh) 2020-05-01
IL279554B2 (en) 2024-12-01
IL279554B1 (en) 2024-08-01
ECSP20075270A (es) 2021-02-26
CL2020003219A1 (es) 2021-06-11
SG11202010450VA (en) 2021-01-28
EA202092451A1 (ru) 2021-03-16
DK3810602T3 (da) 2023-12-11
MD3810602T2 (ro) 2024-03-31
BR112020025869A2 (pt) 2021-03-23
US20200039945A1 (en) 2020-02-06
EP3810602B1 (fr) 2023-11-01
TWI826471B (zh) 2023-12-21
PH12020500673A1 (en) 2021-05-31
RS64932B1 (sr) 2023-12-29
CU20200096A7 (es) 2021-08-06
EP4335439A2 (fr) 2024-03-13
GEP20227403B (en) 2022-08-10
PT3810602T (pt) 2024-01-03
EP4335439A3 (fr) 2024-05-15
PL3810602T3 (pl) 2024-03-04
GB201810092D0 (en) 2018-08-08
PE20210181A1 (es) 2021-01-29
IL279554A (en) 2021-01-31
KR20210022655A (ko) 2021-03-03

Similar Documents

Publication Publication Date Title
MA52948A (fr) Composés
EP3720430A4 (fr) Composés benzocarbonyle
EP3691623A4 (fr) Composés de benzosulfonyle
HUE059403T2 (hu) Vegyületek
MA52489A (fr) Nouveaux composés
EP3956033A4 (fr) Composés bicycliques
MA52560A (fr) Composés hétéroaryles tétracycliques
MA49701A (fr) Composés immunomodulateurs
MA51669A (fr) Composés
IL283692A (en) Novel composition
EP3737672A4 (fr) Composés benzamide
MA53003A (fr) Composés
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP4054724A4 (fr) Composés bifonctionnels
EP3853210A4 (fr) Composés antibactériens
EP3464336A4 (fr) Composés
EP4028399C0 (fr) Composés antibactériens
MA44020A (fr) Composés antitumoraux
MA50504A (fr) Composés antibactériens
MA49621A (fr) Composés bifonctionnels
MA52946A (fr) Composés
MA49522A (fr) Nouveaux composés de quinoléinone
LT3867247T (lt) Naujieji junginiai
MA53430A (fr) Nouveaux composés
DK3808747T3 (da) Imidazopyridinon-forbindelse